For a product that was almost unknown five years ago, cannabidiol (CBD) has taken the health, sports, and wellness and fitness communities by storm. The hemp extract has potent medicinal properties, capable of fighting a long list of ailments, ranging from anxiety and high blood pressure to chronic pain.
Last year the U.S. Food and Drug Administration (FDA) approved Epidiolex, a CBD-derived drug to treat seizures in two rare and hard to manage pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome. Now, results from a recent study show that CBD may also be used to…
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.